在马里疟疾高强度传播季节,成年人接种三剂恶性疟原虫子孢子疫苗的安全性和有效性:一项随机对照1期试验
在非洲马里疟疾高强度传播季节,56名成人先入组开放标签剂量递增预试验,120名成人随机双盲安慰剂对照接种三剂1.8×10^6 PfSPZ疫苗或生理盐水。疫苗耐受性良好,对自然感染的保护效力为51%(95%CI 0.20-0.70)。
要点
- 三剂PfSPZ疫苗耐受性良好,不良事件以轻度为主,疫苗组间无显著差异。
- 预试验中,CHMI后疫苗组0/29、对照组1/15厚血涂片阳性;PCR检出0/29 vs 8/15。
- 主试验24周监测中,疫苗组32/55、对照组42/54厚血涂片阳性,保护效力51%。
核心结论
- 三剂PfSPZ疫苗安全、耐受性良好,对高强度自然恶性疟原虫传播的保护效力为51%,与既往五剂方案报告的52%相似。
研究设计与样本
- 在马里Donéguébougou及周边村庄招募18-50岁健康非孕成人,先进行开放标签剂量递增预试验,随后进行随机双盲安慰剂对照主试验。
- 预试验56人:5人接受4.5×10^5一剂、5人接受9×10^5一剂、30人接受1.8×10^6三剂、15人为CHMI对照、1人接种前退出。
- 主试验120人按村分层随机1:1分配,60人接受三剂1.8×10^6 PfSPZ、60人接受生理盐水,间隔1、13、19周。
- 主要结局为至少一剂疫苗的安全性和耐受性;次要结局为对同源CHMI或自然传播感染的保护效力,采用改良意向性分析(mITT)和符合方案分析。
主要发现
- 所有剂量组接种后不良事件和实验室异常少、以轻度为主,疫苗组间无显著差异(所有p>0.05)。
- 4人发生意外严重转氨酶升高:预试验1.8×10^6疫苗组1人、主试验1.8×10^6疫苗组1人、主试验安慰剂组2人。
- CHMI中,第三剂1.8×10^6后约5周,疫苗组0/29、对照组1/15厚血涂片阳性;PCR检出亚显微感染疫苗组0/29、对照组8/15。
- 主试验24周监测中,疫苗组32/55(58%)、对照组42/54(78%)厚血涂片阳性。
- 保护效力(1-风险比)符合方案分析为0.51(95%CI 0.20-0.70;log-rank p=0.0042),mITT为0.39(95%CI 0.04-0.62;p=0.033);保护效力(1-风险比)符合方案分析为0.24(95%CI 0.02-0.41;p=0.031),mITT为0.22(95%CI 0.01-0.39;p=0.041)。
关键数值与推荐
- 预试验疫苗组:4.5×10^5一剂、9×10^5一剂、1.8×10^6三剂,间隔约8周,直接静脉接种,末剂后5周进行同源CHMI。
- 主试验疫苗组:三剂1.8×10^6 PfSPZ,间隔1、13、19周;对照组:生理盐水。
- 使用复方青蒿素和阿莫地喹清除既往疟原虫感染。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: WHO recently approved a partially effective vaccine that reduces clinical malaria in children, but increased vaccine activity is required to pursue malaria elimination. A phase 1 clinical trial was done in Mali, west Africa, to assess the safety, immunogenicity, and protective efficacy of a three-dose regimen of Plasmodium falciparum sporozoite (PfSPZ) Vaccine (a metabolically active, non-replicating, whole malaria sporozoite vaccine) against homologous controlled human malaria infection (CHMI) and natural P falciparum infection. METHODS: We recruited healthy non-pregnant adults aged 18-50 years in Donéguébougou, Mali, and surrounding villages (Banambani, Toubana, Torodo, Sirababougou, Zorokoro) for an open-label, dose-escalation pilot study and, thereafter, a randomised, double-blind, placebo-controlled main trial. Pilot study participants were enrolled on an as-available basis to one group of CHMI infectivity controls and three staggered vaccine groups receiving: one dose of 4·5 × 105, one dose of 9 × 105, or three doses of 1·8 × 106 PfSPZ via direct venous inoculation at approximately 8 week intervals, followed by homologous CHMI 5 weeks later with infectious PfSPZ by direct venous inoculation (PfSPZ Challenge). Main cohort participants were stratified by village and randomly assigned (1:1) to receive three doses of 1·8 × 106 PfSPZ or normal saline at 1, 13, and 19 week intervals using permuted block design by the study statistician. The primary outcome was safety and tolerability of at least one vaccine dose; the secondary outcome was vaccine efficacy against homologous PfSPZ CHMI (pilot study) or against naturally transmitted P falciparum infection (main study) measured by thick blood smear. Combined artesunate and amodiaquine was administered to eliminate pre-existing parasitaemia. Outcomes were analysed by modified intention to treat (mITT; including all participants who received at least one dose of investigational product; safety and vaccine efficacy) and per protocol (vaccine efficacy). This trial is registered with ClinicalTrials.gov, number NCT02627456. FINDINGS: Between Dec 20, 2015, and April 30, 2016, we enrolled 56 participants into the pilot study (five received the 4·5 × 105 dose, five received 9 × 105, 30 received 1·8 × 106, 15 were CHMI controls, and one withdrew before vaccination) and 120 participants into the main study cohort with 60 participants assigned PfSPZ Vaccine and 60 placebo in the main study. Adverse events and laboratory abnormalities post-vaccination in all dosing groups were few, mainly mild, and did not differ significantly between vaccine groups (all p>0·05). Unexpected severe transaminitis occured in four participants: one participant in pilot phase that received 1·8 × 106 PfSPZ Vaccine, one participant in main phase that received 1·8 × 106 PfSPZ Vaccine, and two participants in the main phase placebo group. During PfSPZ CHMI, approximately 5 weeks after the third dose of 1·8 × 106 PfSPZ, none of 29 vaccinees and one of 15 controls became positive on thick blood smear; subsequent post-hoc PCR analysis for submicroscopic blood stage infections detected P falciparum parasites in none of the 29 vaccine recipients and eight of 15 controls during CHMI. In the main trial, 32 (58%) of 55 vaccine recipients and 42 (78%) of 54 controls became positive on thick blood smear during 24-week surveillance after vaccination. Vaccine efficacy (1-hazard ratio) was 0·51 per protocol (95% CI 0·20-0·70; log-rank p=0·0042) and 0·39 by mITT (0·04-0·62; p=0·033); vaccine efficacy (1-risk ratio) was 0·24 per-protocol (0·02-0·41; p=0·031) and 0·22 mITT (0·01-0·39; p=0·041). INTERPRETATION: A three-dose regimen of PfSPZ Vaccine was safe, well tolerated, and conferred 51% vaccine efficacy against intense natural P falciparum transmission, similar to 52% vaccine efficacy reported for a five-dose regimen in a previous trial. FUNDING: US National Institute of Allergy and Infectious Diseases, National Institutes of Health, Sanaria. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect Dis. 2021. PMID: 34801112. doi:10.1016/S1473-3099(21)00332-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。